At ISPOR Montreal 2025 Conference, CapeStart, announced a major new release of MadeAi™-its award-winning generative AI-based platform that expedites the synthesis of content and data for the life sciences, helping time-strapped teams to scale faster, strengthen regulatory submissions, and advance the pace of scientific research.
MadeAi first launched in November of 2024 with MadeAi-LR, a GenAI-enabled software solution leveraging the MadeAi platform to streamline key applications used in new therapy development including systematic literature reviews (SLR), clinical evidence reports (CERs), meta-analysis, targeted literature reviews (TLRs), and other clinical literature assessments. MadeAi-LR cuts literature review time in half while centralizing the process with an end-to-end platform, delivering 90% accuracy, and providing sourcing and attribution along the way for verifiable, traceable, and trustworthy results.
Developed with top 15 pharmaceutical companies, MadeAi-LR centralizes the literature review workflow, while bringing full sourcing attribution and transparency into research decision considerations. It frees teams to focus on higher-value work while driving greater productivity, stronger regulatory submissions, sharper internal strategies, and deeper research. With a single review demanding hundreds of onerous hours, MadeAi-LR helps pharma, biotech, and medtech organizations save time, stretch critical resources, and scale research to accelerate innovation.
Also Read: Pangea Laboratory Appoints John Moore as Chief Executive Officer
“MadeAi-LR customers are completing more literature reviews in less time and seeing immediate ROI, and they’re eager for us to evolve our platform to address their more complex research needs,” said Gaugarin Oliver, founder and CEO of CapeStart. “Our latest release offers enhancements that allow the GenAI to support more dynamic aspects of literature review research-including AI as Reviewer, Arm-level Extraction, and Quality Appraisals, among other improvements—so teams can scale faster and focus on what matters most: advancing science.”
SOURCE: Businesswire